ArticleJournal of radiation research2026
Feasibility of online adaptive SBRT boost with 1.5-T MR-Linac for cervical cancer patients unsuitable for brachytherapy: a planning study.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effectiveness of online adaptive treatment (ADT) planning for stereotactic body radiotherapy (SBRT) boost on a 1.5-T MR-Linac in cervical cancer patients ineligible for brachytherapy, compared with the conventional position-alignment (PA) assumed dose distributions. This retrospective analysis included 15 treatment plans from five patients, each receiving 21.0 Gy in three fractions. Daily magnetic resonance imaging (MRIs) were used to compare target and organ-at-risk (OAR) doses between ADT and PA dose distributions. The planning target volume (PTV) was defined as the high-risk clinical target volume (HR-CTV) plus a 3 mm margin. OARs included the bladder, bowel bag, and planning organ-at-risk volume (PRV) for rectum and sigmoid. Reference plans prioritized OAR constraints while maximizing target coverage; the intended PTV D90% range was 18.9-21.6 Gy. PA doses were reconstructed by dose warping based on alignment of the anterior rectal wall between daily and pretreatment MRIs, whereas ADT plans were reoptimized on the daily MRIs. HR-CTV decreased by 1.6%-41.5% between the planning MRI and the first treatment fraction. ADT plans improved PTV D90%, achieved better target coverage and met all OAR constraints, whereas PA plans showed dose constraint exceedance across the three fractions, with mean excess doses of 6.89 ± 4.39 Gy to PRV-sigmoid and 5.76 ± 3.33 Gy to PRV-rectum. In conclusion, 1.5-T MR-Linac based SBRT boost with daily online adaptation enhanced tumor coverage and reduced OAR doses, supporting MR-guided online adaptive radiotherapy as a promising option for patients ineligible for brachytherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.